Metabolic Impact of Fructose Restriction in Obese Children (SUCRE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01200043|
Recruitment Status : Completed
First Posted : September 13, 2010
Last Update Posted : May 14, 2018
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Obesity Metabolic Syndrome||Other: fructose restriction diet||Not Applicable|
Recent studies suggest that specific types of macronutrients in the diet may have selective effects on nutrient absorption, insulin sensitivity, and lipid metabolism. Elucidation of the metabolic impact of specific dietary components may well result in improved efficacy of lifestyle approaches to reduce obesity and metabolic diseases. Despite similar fructose consumption, the phenotype of co-morbidities is different between African Americans and Latinos. Latino and Caucasian children manifest worsened dyslipidemia and non-alcoholic fatty liver disease (NAFLD), while African American children manifest worsened insulin resistance and hypertension. We have also documented in adults that a reduction in de novo lipogenesis (DNL; production of new lipids) in the liver and liver fat content, and improvement in hepatic insulin sensitivity were achieved by substitution of complex carbohydrate for fructose; but these changes appeared less dramatic in African American compared to Latino or Caucasian subjects. These divergent findings suggest ethnic and race-specific differences of fructose metabolism and disposition.
To determine whether fructose is a contributor to metabolic co-morbidity in children, we will conduct a convenience cohort within-subject intervention with repeated measures, stratified by racial/ethnic group (Latinos vs. African Americans vs. Caucasians). The intervention will consist of restricting fructose ingestion only to naturally-occurring fructose in fruits and vegetables (approximately 15 gm/day for 10 days), by substituting complex carbohydrate for excess dietary fructose, while maintaining neutral energy balance. We anticipate fructose restriction to differentially improve co-morbidities in different racial/ethnic groups.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||54 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Metabolic Impact of Fructose Restriction in Obese Children|
|Study Start Date :||July 2010|
|Actual Primary Completion Date :||December 2014|
|Actual Study Completion Date :||December 1, 2014|
Experimental: fructose restriction
Isocaloric fructose restricted diet for 10 days
Other: fructose restriction diet
fruits and vegetables only
- intrahepatic fat content [ Time Frame: 10 days ]We anticipate fructose restriction to reduce intrahepatic fat, exclusive of calories
- insulin resistance [ Time Frame: 10 days ]We anticipate fructose restriction will improve insulin sensitvity exclusive of calories
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||8 Years to 18 Years (Child, Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- African-American, Latino, and Caucasian boys and girls. Ethnicity is to be determined by self-report. Utilizing the US Census Bureau procedures, participants will be asked two questions, the first regarding ethnicity and the second on race. Subjects will be given the opportunity to select more than one racial category.
- Ages 8 to 18 yr. The minimum age cutoff is due to our desire not to sedate younger children for the magnetic resonance spectroscopy scan or magnetic resonance scan (MRS, MRI). We chose to study these groups because they are most affected by metabolic syndrome and manifest the greatest morbidities; yet their presentations are different from each other.
The following criteria are modified from the National Cholesterol Education Program's Adult Treatment Panel and the World Health Organization definition of metabolic syndrome. Waist circumference is not an adequate predictor of visceral adiposity in children. Also, no normative values have been developed nor is this measurement consistent between racial and ethnic groups. Body mass index (BMI), however, correlates strongly with both visceral lipid depot and blood pressure. The definition of hypertension is greater than the 95th percentile for sex and age as designated in the 1996 Task Force Report on High Blood Pressure in Children and Adolescents.
- Obesity, as defined by BMI z-score of 2.0 or greater, or above the 97th percentile for age and sex; and weight ≥40 kg.
- Hyperinsulinemia (fasting insulin >15 µU/mL), or insulin resistant (HOMA > 4.3). See details below.
- At least one of the following: systolic blood pressure above the 95th percentile for age and sex, or triglyceride level above the 95th percentile for age, sex and race or ethnic group as established by the 1998 National Heart, Lung, and Blood Institute Growth and Health Study.
- History of disorders other than obesity that may affect insulin levels, such as Cushing's syndrome, diabetes mellitus, or depression.
- Medications that may affect insulin sensitivity or hepatic lipid content, e.g. metformin, steroids, atypical antipsychotics, anti depressants, statins, Vitamin E, thyroid medications, anti-hypertensives, weight loss medications, oral contraceptives.
- Pregnancy or lactation.
- Surgical procedures for obesity.
- History consistent with obstructive sleep apnea.
- Implants including intracranial surgical clips, pacemakers, and other metals or implants that preclude MR scanning.
- Inability to fit within the MR bore: shoulder to shoulder width of greater than 58 cm or anterior-posterior length greater than 35 cm (magnet bore size limitation).
- Weight greater than 320 pounds (MRS table weight limitation).
- Eating disorders.
- Smoking or alcohol use. Subjects will answer the two questions on the Alcohol Query Form. Any consumption of more than 2 drinks per month will
- Vegan diet.
- All subjects with known diabetes mellitus according to the 1997 ADA criteria will be excluded. However, subjects with known impaired glucose tolerance (fasting glucose 101-125, and 2-hour post-prandial glucose level between 141-200) can remain eligible.
- Syndromic patients (e.g. Prader-Willi, Bardet-Biedl) will be excluded, as it is likely that the reasons for their obesity may be neurologic or single-point mutations, and are likely to be different from those causing the Metabolic Syndrome.
- Subjects who are found to be hypothyroid by clinical exam or by evaluation of thyroid function tests on first visit to the WATCH Clinic will receive L-thyroxine for three months, with documentation of adequate replacement, prior to enrollment in the protocol.
- Subjects with a history of hepatitis will be excluded from the study. However, patients with NAFLD, as determined by Dr. P. Rosenthal (Ped. Hepatology, UCSF), may participate. Upper cutoffs for AST and ALT will be 5 times the upper limit of normal for the UCSF laboratory.
- Subjects with any history of renal disease will be excluded.
- Subjects who have a fever or an active infection will be postponed until their infection remits.
- Emancipated minors will be excluded, as there will be no parental supervision and monitoring over the subject's diet during the 9 days of fructose restriction.
- Females who have achieved menarche will have a urine pregnancy test at the time of their DEXA scans. A positive pregnancy test will lead to exclusion of the data from further analysis. Results of a positive pregnancy test will be transmitted to the minor only, and the parents will be told only that the subject does not qualify for the study.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01200043
|United States, California|
|San Francisco, California, United States, 94143|
|Principal Investigator:||Robert Lustig, MD||University of California, San Francisco|
|Responsible Party:||University of California, San Francisco|
|Other Study ID Numbers:||
R01DK089216 ( U.S. NIH Grant/Contract )
|First Posted:||September 13, 2010 Key Record Dates|
|Last Update Posted:||May 14, 2018|
|Last Verified:||May 2018|
Glucose Metabolism Disorders